Document is current
Any future updates will be listed below
-
Authors
Zhang, Jianye
Hołubowicz, Rafał
Smidak, Roman
Hu, Yulun https://orcid.org/0000-0002-2181-1182
Du, Samuel W. https://orcid.org/0000-0002-9655-3659
Felgner, Jiin H.
Palczewska, Grazyna
Rodrigues Menezes, Carolline
Risaliti, Eleonora https://orcid.org/0009-0006-9689-7474
Dong, Zhiqian https://orcid.org/0000-0002-8748-4532
Ma, Xiuli
Shayegan, Mojtaba H.
Chen, Paul Z.
Xing, Li https://orcid.org/0000-0001-7612-602X
Hołubowicz, Maria
Li, Bowen
Liu, David R.
Felgner, Philip L.
Tochtrop, Gregory P. https://orcid.org/0000-0003-2447-254X
Palczewski, Krzysztof https://orcid.org/0000-0002-0788-545X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY009339; R01EY030873, P30EY034070)
U.S. Department of Health & Human Services | NIH | National Eye Institute (T32GM008620; F30EY033642)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30CA062203)
National Science Foundation (CHE-1904530)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 17 May 2025
Accepted: 22 January 2026
First Online: 7 February 2026
Competing interests
: K.P. is a consultant for Polgenix Inc. and AbbVie Inc., and serves on the Scientific Advisory Board of Hyperion Eye Ltd. K.P. and G.P.T. are equity holders in Eyesomer Therapeutics. D.R.L. is a consultant and/or equity owner for Prime Medicine, Beam Therapeutics, Pairwise Plants, and nChroma Bio, companies that use or deliver genome-editing or epigenome-engineering agents. All other authors have declared that no competing interests exist.
